C5 and myasthenia gravis: Eculizumab was approved by the US Food and Drug Administration (FDA) and European Medicines Agency in 2017 for AChR-positive MG [29, 30] and has since been joined by two further C5 inhibitors (Fig. 2 and Table 1) [31–35].